Advanced Filters
noise

Pneumonia Clinical Trials

A listing of Pneumonia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,323 clinical trials
S Stephen E. Spurgeon

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain …

18 - 75 years of age All Phase 1/2
A Adriana Balduzzi

Precision Exercise in Children With Malignant Hemopathies

In the early years of life and during adolescence, physical activity is crucial for good development of motor skills. It is even more so for those children and young people who are forced to undergo anti-cancer therapies and therefore undergo long periods of hospitalization (often bedridden) and prolonged periods of …

2 - 18 years of age All Phase N/A
S Seoul National University Bundang Hospital

Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma

The study will include 28 patients with primary CNS DLBCL who are ineligible with autologous hematopoietic stem cell transplantation or whole brain radiation therapy as consolidation therapy. Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented …

19 years of age All Phase 2
L Liren Qian, M.D.

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory angioimmunoblastic T-cell lymphoma.

18 years of age All Phase 1/2
W Wenbin Qian

Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

This phase Ib/II trial is evaluating the efficacy and side effect of orelabrutinib and sintilimab as possible treatments for relapsed or refractory central nervous system lymphoma.

18 - 75 years of age All Phase 1/2
V Vincent CAMUS, MD

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients …

18 years of age All Phase N/A
Z Zhihua Yao, M.D. Ph.D

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.

18 - 75 years of age All Phase 2
M Maya Aslam

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This trial aims to see whether MRI using hyperpolarized carbon-13 pyruvate is safe and useful for detecting central nervous system lymphoma and evaluating …

18 years of age All Phase 1
H Ho Sup Lee, MI

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Induction chemotherapy 1) RCHOP(Rituximab+Cyclophosphamide+Doxorubicin+Vincristine+Prednisone) 2) VR-CAP (Bortezomib+Rituximab+Cyclophosphamide+Doxorubicin+Prednisone) Patients who have received induction chemotherapy will be evaluated for responses and those who achieved more than PR(Partial response) or PR will be eligible for this study after receiving informed consents. 2. Experimental step Maintenance ixazomib beginning at least 8 weeks after completion …

19 years of age All Phase 2
J Jun-ping Zhang

Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.

18 years of age All Phase 2

Simplify language using AI